CompMedChem
康迈迪森科技
CompMedChem (康迈迪森) is an AI-driven drug discovery company set up in 2020, co-initiated by founder Dr. Wan Xiaobo together with Dr. Huang Niu (senior investigator at the National Institute of Biological Sciences, Beijing), Dr. Shan Bei (founder of BioMap/百放英库), and FreeS Fund . It closed an angel round at the end of 2020 led by FreeS Fund, with BioMap participating . FreeS Fund, where partner Rui Ma covers the computational-driven biotech space, lists it among its AI-pharma portfolio alongside companies like XtalPi (晶泰科技) and METiS (剂泰医药) .
That's about the extent of elsewhere's coverage — the corpus carries no dedicated feature on the company, so details like its pipeline or later financing rounds aren't documented here.
AI-generated — may contain errors, please verify.
Coverage
Are Returnee Entrepreneurs Losing Their Edge? | 2021 FreeS Fund China-US Venture Forum Transcript
Launch a Startup or Take the "Soft Landing" Through Employment?
What's It Like Doing Venture Capital in China? | 2021 FreeS Fund China-US VC Forum Transcript
How do you know if you're cut out for investing? What challenges will you face along the way?
FreeS Report 21: In Search of China's Classics and Fashion — A Study on Guochao Consumption | FreeS Research Institute
Every category will see the rise of influential guochao brands.
FreeS Fund China-US Venture Capital Forum Registration Now Open | Seizing New Opportunities in China's Era
Whether you're looking for a job or starting a company, feel free to come chat with us at FreeS Fund.
